

Table S7: Association between wheeze phenotypes at age 2 and age 6 years

Phenotype	N*	No wheeze at	EVW at follow-up			MTW at follow-up		
at baseline	(100 %)	follow-up	n (%)	Crude RRR†	Adj. RRR†‡	n (%)	Crude RRR†	Adj. RRR†‡
		n (%)		(95% CI)	(95% CI)		(95% CI)	(95% CI)
ALSPAC								
No wheeze	5854	5539 (94.6)	108 (1.8)	1	1	207 (3.5)	1	1
EVW	532	403 (75.8)	63 (11.8)	8.0 (5.8, 11.1)	3.2 (2.0, 5.2)	66 (12.4)	4.4 (3.3, 5.9)	1.7 (1.2, 2.6)
MTW	585	378 (64.6)	34 (5.8)	4.6 (3.1, 6.9)	1.3 (0.7, 2.4)	173 (29.6)	12.2 (9.8, 15.4)	3.4 (2.3, 5.1)
LRC								
No wheeze	1212	1111 (91.7)	28 (2.3)	1	1	73 (6.0)	1	1
EVW	156	112 (71.8)	22 (14.1)	7.8 (4.3, 14.1)	4.6 (2.0, 10.3)	22 (14.1)	3.0 (1.8, 5.0)	1.6 (0.8, 3.2)
MTW	183	105 (57.4)	8 (4.4)	3.0 (1.3, 6.8)	1.4 (0.4, 4.9)	70 (38.2)	10.1 (6.9, 14.9)	3.6 (1.7, 7.7)

Abbreviations: ALSPAC Avon Longitudinal Study on Parents and Children, LRC Leicestershire Respiratory Cohort 1998-b, EVW episodic viral wheeze, MTW multiple trigger wheeze

* Numbers include only children with classifiable wheeze (see Table 1) or no wheeze at baseline and follow-up

† Results from multinomial regression analysis including non-classifiable wheeze (see Table 1) but results for this category are not reported here.

‡ Adjusted symptom severity at baseline (frequent attacks, shortness of breath, sleep disturbance, interference with activities and speech limitation).